行情

BLCM

BLCM

Bellicum制药
NASDAQ

实时行情|Nasdaq Last Sale

4.350
-0.360
-7.64%
已收盘, 16:00 04/01 EDT
开盘
4.590
昨收
4.710
最高
5.01
最低
4.227
成交量
13.94万
成交额
--
52周最高
40.50
52周最低
3.320
市值
2,195.83万
市盈率(TTM)
-0.0181
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BLCM价格均价为17.25,最高价位25.00,最低价为9.00。

EPS

BLCM 新闻

更多
  • 波音将向员工提供工龄买断和提前退休计划
  • 新浪财经 · 1小时前
  • 新华社:新冠肺炎疫情或致美国制造业深陷衰退危机
  • 新华网 · 2小时前
  • 沪指低开高走 疫情数据双重打击、隔夜美股重挫4.4%
  • 新浪财经 · 2小时前
  • 菲律宾总统下令隔离期间制造麻烦者格杀勿论
  • 新浪财经 · 3小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

BLCM 简况

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
展开

微牛提供Bellicum Pharmaceuticals Inc(NASDAQ-BLCM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BLCM股票新闻,以帮助您做出投资决策。